Health TrialsbyHealthPanel

An International Study on Pediatric Patients With Rare Tumors.

ConditionsParaganglioma/ PhaeochromocytomaMelanoma and Other Malignant Neoplasms of SkinGastrointestinal Stromal Tumor (GIST)Adrenocortical TumorPancreatic TumorsEsthesioneuroblastoma, OlfactoryMesotheliomaNasopharyngeal Carcinoma (NPC)NUT CarcinomaPleuropulmonary BlastomaSalivary Gland TumorsThymic TumorsThyroid CarcinomaAppendiceal Cancers
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-18
SponsorAzienda Ospedaliera di Padova

About this trial

The PARTNER study is an international, prospective, observational study of paediatric patients with very rare tumours.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Children and adolescents (age 0-18 years) with a primary or relapsed Very Rare Tumor diagnosed and/or treated in a participating country/center.

Written informed consent from the patient and/or the parent/legal guardian

Disqualifiers

Absence of Written informed consent from the patient and/or the parent/legal guardian

Trial population

Children and adolescents (0-18 years) with a primary or relapsed Very Rare Tumor (VRT)

Trial design

Design model

Other

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Trial outcomes

Primary outcomes

1

Epidemiology

Evaluate the number of patients (aged 0-18 years) with different Very Rare Tumors in the different countries: observed cases will be compared with expected cases.

Time frame
through study completion, an average of 1 year
2

Use of International Recommendations

The study aims to measure the number of patients treated for different neoplasms in different countries, and the proportion of those treated in accordance with the International Recommendations.

Time frame
through study completion, an average of 1 year
3

Survival of children and adolescents (0-18 years) affected by Very Rare Tumors

The study will correlate the clinical characteristics of the tumor (size, site, extension) with the treatment, the risk of recurrence and survival.

Time frame
through study completion, an average of 1 year

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Azienda Ospedaliera di Padova

Lead sponsor

St. Anna Children's Hospital, Vienna

Collaborator

Children's Hospital Zagreb

Collaborator

Centre Hospitalier Universitaire de La Réunion, FRANCE

Collaborator

Klinikum Dortmund

Collaborator

University Children's Hospital Tuebingen

Collaborator

Hellenic Oncology Research Group

Collaborator

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Collaborator

Kaplan Medical Center, Rehovot, Israel

Collaborator

Vilnius University Hospital Santaros Klinikos

Collaborator

University of Skopje

Collaborator

Gdansk Medical University (Poland)

Collaborator

Centro Hospitalar do Porto

Collaborator

Bucharest Emergency Hospital

Collaborator

Institute for Oncology and Radiology Serbia, Belgrade

Collaborator

University Hospital Bratislava

Collaborator

University Medical Centre Ljubljana

Collaborator

University of Bilbao

Collaborator

Göteborg University

Collaborator

University Hospital, Paris

Collaborator

Source ClinicalTrials.gov
Apply now